Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.23.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development (including related party purchases of $421 and $243 for the three months ended September 30, 2023 and 2022, respectively, $1,335 and $1,470 for the nine months ended September 30, 2023 and 2022, respectively.) $ 100,559 $ 73,870 $ 264,926 $ 220,146
Selling, general and administrative (including related party purchases of $69 and $46 for the three months ended September 30, 2023 and 2022, respectively, $232 and $335 for the nine months ended September 30, 2023 and 2022, respectively.) 27,608 23,251 78,926 70,700
Total operating expenses 128,167 97,121 343,852 290,846
Loss from operations (128,167) (97,121) (343,852) (290,846)
Interest and other income, net 13,611 5,360 32,694 8,671
Income from equity method investment 0 0 0 19,039
Gain (Loss) from change in fair value of warrants and earnout shares 116,109 12,560 (86,671) 72,072
Total other income (loss), net 129,720 17,920 (53,977) 99,782
Income (Loss) before income taxes 1,553 (79,201) (397,829) (191,064)
Income tax expense 28 5 118 35
Net income (loss) $ 1,525 $ (79,206) $ (397,947) $ (191,099)
Net income (loss) per share, basic (in dollars per share) $ 0.00 $ (0.14) $ (0.62) $ (0.33)
Net income (loss) per share, diluted (in dollars per share) $ 0.00 $ (0.14) $ (0.62) $ (0.33)
Weighted-average common stock outstanding, basic (in shares) 672,559,810 583,970,409 638,388,011 581,458,391
Weighted-average common stock outstanding, diluted (in shares) 691,455,162 583,970,409 638,388,011 581,458,391